Malin Corporation PLC
ISEQ:MLC
Intrinsic Value
Malin Corp. Plc.invests and supports innovative life sciences companies, which develops exceptional science and technology to deliver transformative outcomes for patients. [ Read More ]
The intrinsic value of one MLC stock under the Base Case scenario is 8.43 EUR. Compared to the current market price of 5.9 EUR, Malin Corporation PLC is Undervalued by 30%.
Valuation Backtest
Malin Corporation PLC
Run backtest to discover the historical profit from buying and selling MLC stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Malin Corporation PLC
| Current Assets | 175.1m |
| Cash & Short-Term Investments | 173.9m |
| Receivables | 1.2m |
| Non-Current Assets | 112.8m |
| Long-Term Investments | 102.1m |
| PP&E | 100k |
| Other Non-Current Assets | 10.6m |
| Current Liabilities | 600k |
| Accounts Payable | 600k |
| Non-Current Liabilities | 4.2m |
| Other Non-Current Liabilities | 4.2m |
Earnings Waterfall
Malin Corporation PLC
|
Revenue
|
0
EUR
|
|
Operating Expenses
|
-4.5m
EUR
|
|
Operating Income
|
-4.5m
EUR
|
|
Other Expenses
|
4.5m
EUR
|
|
Net Income
|
0
EUR
|
Free Cash Flow Analysis
Malin Corporation PLC
MLC Profitability Score
Profitability Due Diligence
Malin Corporation PLC's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
Score
Malin Corporation PLC's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
MLC Solvency Score
Solvency Due Diligence
Malin Corporation PLC's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Malin Corporation PLC's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MLC Price Targets Summary
Malin Corporation PLC
According to Wall Street analysts, the average 1-year price target for MLC is 8.07 EUR with a low forecast of 7.99 EUR and a high forecast of 8.31 EUR.
Shareholder Return
MLC Price
Malin Corporation PLC
| Average Annual Return | 13.23% |
| Standard Deviation of Annual Returns | 36.79% |
| Max Drawdown | -71% |
| Market Capitalization | 111m EUR |
| Shares Outstanding | 18 810 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Malin Corp. Plc.invests and supports innovative life sciences companies, which develops exceptional science and technology to deliver transformative outcomes for patients. The company is headquartered in Dublin, Dublin and currently employs 5 full-time employees. The company went IPO on 2015-03-25. The Company’s assets give investors access to life sciences businesses with exposure across diverse modalities, therapeutic areas and geographies. Its business includes Poseida, Viamet, Xenex, CG Oncology, Wren, KNOW Bio and Artizan. Poseida is a clinical-stage biopharmaceutical company building a pipeline of Chimeric antigen receptor T cell (CAR-T) product candidates, initially focused on the treatment of hematological malignancies, including multiple myeloma, and solid tumours, like prostate cancer. The company is also developing two CAR-T therapies: autologous and allogeneic. Xenex is a commercial-stage medical device company focused on reducing healthcare-associated infections with its non-mercury, full-spectrum disinfection LightStrike Germ-Zapping robots. CG Oncology is an oncolytic immunotherapy company that is intensely focused on developing bladder-saving therapeutics for patients with bladder cancer.
Contact
IPO
Employees
Officers
The intrinsic value of one MLC stock under the Base Case scenario is 8.43 EUR.
Compared to the current market price of 5.9 EUR, Malin Corporation PLC is Undervalued by 30%.
You don't have any saved screeners yet
